Particle Health

The durable asset is the interoperability network: connections to national health information networks, identity resolution, and record retrieval at a reported 320 million record scale. That is infrastructure, not inference. The AI is a real and growing layer on top, covering summarization through Snapshot, discharge summary generation, and model based clinical document parsing that the company argues outperforms template based CCDA extraction. A customer buys the data access first and the enrichment second, which is what this grade describes. This is the same pattern as Helix, where the network is the moat and the models are the layer.

Unusually candid engineering disclosure for a data vendor. Published writing explains why template based CCDA parsing drops clinically important medications and what was built instead, and argues that discharge alerting fails on identity resolution rather than event delivery. Naming your own failure modes in public is a stronger transparency signal than a capability list. Held back from A because no model detail, benchmark, or accuracy measurement for the summarization and parsing products was retrieved.

The company operates under the interoperability and information blocking rules and handles the query attribution requirements that health information networks impose, which is a real compliance function. However the platform explicitly positions retrieved clinical data as a resource for training AI models, and no disclosure was retrieved covering consent scope for that secondary use, de identification standard, or customer controls over it. For a vendor whose product is bulk access to identified clinical records, that is the disclosure a buyer most needs and it is absent.

This is the product and the coverage is specific: a single bidirectional API spanning CommonWell, Carequality, and eHealth Exchange plus ADT feeds and prescription data, reaching a reported 70,000 healthcare organizations and locating roughly 90 percent of patients nationally, returned in structured FHIR. Particle for Platforms additionally handles the query permission and attribution burden for health IT vendors who lack a direct treatment relationship with patients, which is a genuine regulatory constraint rather than a feature.

No public pricing. Contact the vendor. Sold to health technology companies, payers, and care organizations, with a platform tier for health IT vendors serving many downstream clients. Buyers should establish whether pricing is per query, per patient record, or subscription, since retrieval volume drives cost in very different ways under each.